SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001867096-24-000024
Filing Date
2024-03-06
Accepted
2024-03-06 07:27:40
Documents
18
Period of Report
2024-03-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K xers-20240305.htm   iXBRL 8-K 37815
2 EX-99.1 exh991q42023earningsrelease.htm EX-99.1 116080
3 EX-99.2 exh992pressreleasedatedmar.htm EX-99.2 16788
7 picture1reviseda.jpg GRAPHIC 4446
8 picture1revisedb.jpg GRAPHIC 4446
  Complete submission text file 0001867096-24-000024.txt   332342

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xers-20240305.xsd EX-101.SCH 1901
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xers-20240305_lab.xml EX-101.LAB 22548
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xers-20240305_pre.xml EX-101.PRE 13046
19 EXTRACTED XBRL INSTANCE DOCUMENT xers-20240305_htm.xml XML 2833
Mailing Address 1375 WEST FULTON STREET, SUITE 1300 CHICAGO IL 60607
Business Address 1375 WEST FULTON STREET, SUITE 1300 CHICAGO IL 60607 844-445-5704
Xeris Biopharma Holdings, Inc. (Filer) CIK: 0001867096 (see all company filings)

IRS No.: 871082097 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40880 | Film No.: 24724374
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)